Portfolio Company · Operating Co.

Catalent Pharma Solutions

Healthcare

backed byGenstar Capital

ExitedHealthcare

a portfolio company of

Genstar Capital

Status on record: Exited

PE Firm Index

Who owns Catalent Pharma Solutions?

Catalent Pharma Solutions is listed as an exited portfolio company of Genstar Capital on Genstar Capital's own portfolio page.

Company Snapshot

Catalent Pharma Solutions is a Healthcare company. Its owner on record, Genstar Capital, is a leveraged buyout firm founded in 1988, headquartered in San Francisco, United States, with $49 billion under management. Genstar Capital lists at least 84 companies in the index, 13 of them in Healthcare.

SectorHealthcare

Parent PE firmGenstar Capital

Ownership statusExited

WebsiteNot on record

About the owner

Genstar Capital

Headquarters: San Francisco, United States
Founded: 1988
AUM: $49 billion
Strategy: Leveraged Buyout, Growth Capital, Middle-market Buyouts
Target size: Middle-market companies
Sectors: Financial Services, Software, Industrial Technology
Companies in the index: At least 84

Genstar Capital is an American private equity firm focused on middle-market investments in North America.

Read the Genstar Capital profile

Questions about Catalent Pharma Solutions

Who owns Catalent Pharma Solutions?

Catalent Pharma Solutions is listed as an exited portfolio company of Genstar Capital on Genstar Capital's own portfolio page.

What sector is Catalent Pharma Solutions in?

Catalent Pharma Solutions is in Healthcare. Classified from the owner's portfolio label.

Where is Genstar Capital headquartered?

Genstar Capital is headquartered in San Francisco, United States.

What else does Genstar Capital own in Healthcare?

Genstar Capital lists 12 other Healthcare companies in the index, including Advarra, Association Member Benefits Advisors, Axia, ConnectiveRx and eResearch Technologies.

Sources

Genstar Capital
https://www.gencap.com/companies/

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Catalent Pharma Solutions and does not provide investment advice.

Other portfolio companies of Genstar Capital

6 of 83 shown

2-10 Home Buyers Warranty

See the full Genstar Capital portfolio.

Other Healthcare companies held by Genstar Capital

Advarra Association Member Benefits Advisors Axia

ConnectiveRx eResearch Technologies Evolution1

Other Healthcare portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Genstar Capital

San Francisco, United States

Status: Exited

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.